Plasma Exchange Rebound
Plasma Exchange Rebound: Why Levels Climb Back After a Session, What Sets How Fast, and How That Shapes the Number of Sessions
Plasma exchange has a part that happens after the machine is switched off, and that part decides most of what follows. When plasma is removed and replaced, the level of a substance in the blood drops. Then, over the next hours and days, it climbs back. That return is called rebound, and it explains why one session rarely does what people expect, why sessions in a series are spaced the way they are and why no one can responsibly offer a session count before they know what is being lowered and how fast it returns.
This article follows rebound from first principles. It explains the arithmetic of a single exchange, where the returning substance comes from, how production by the body pushes levels back up, how that plays out in three invented examples, why spacing matters, how labs should be timed around a session and what repetition costs the body. It is written by the team at Liondale Medical in New York, where Dr. Lionel Bissoon supervises therapeutic plasma exchange as a physician-led procedure. It does not recommend a particular schedule for any reader, and it does not promise a result.
What One Exchange Leaves Behind When the Machine Stops
The standard unit is the plasma volume, which is the total volume of plasma in a person's circulation. It depends on body size and on hematocrit, the share of blood that is cells. A typical adult has roughly three liters of plasma, though the figure varies widely.
When one plasma volume is exchanged, the concentration of a substance that remains in the bloodstream falls by roughly 60 to 65 percent, not to zero. The reason is that the replacement fluid is mixing with the patient's remaining plasma as the exchange proceeds, so some of what is removed is diluted material and not original. The relationship is exponential, which means each additional plasma volume removes a smaller absolute amount than the one before.
Exchanging one and a half plasma volumes lowers the substance more, perhaps by about 75 percent. Exchanging two volumes lowers it further, to around 85 percent, but takes longer, uses more fluid and increases exposure to the risks of the procedure. This is why standard practice settles near one to one and a half plasma volumes per session, rather than chasing completeness in a single sitting.
That figure describes the level at the end of the session, and it is the lowest the level will be. Everything after that moment is rebound.
Where the Returning Substance Comes From
The arithmetic above assumes that a substance sits only in the plasma. In real bodies, many substances are distributed between the blood and the tissues around the vessels, and they flow between the two to keep balance.
When plasma is removed, the concentration in the blood falls, and substances in the tissues then move back into the blood to restore equilibrium. This is rebound. For a substance with a large tissue reservoir, a considerable portion of the removed amount can return within a day or two. For one that is largely confined to the blood, rebound is minimal.
Production adds a second force. The body continues to make the substance it has lost. A protein made rapidly will be replenished quickly, while one made slowly stays low longer. Antibodies, for example, are produced by immune cells, and in an autoimmune condition the cells keep producing them, which is why plasma exchange is often combined with medicines that reduce production.
Together, redistribution and production determine how long a single exchange has an effect. Without knowing a substance's distribution and turnover, no one can say how long the lowered level will last or how many sessions are needed to keep it lower. This is why the answer varies with the target.
Three Invented Curves: Slow Production, Fast Production and a Tissue Reservoir
A simple illustration, using invented figures, shows how these pieces fit together. It is not a schedule for anyone.
Suppose a harmful protein sits at a level of 100 units, stays mostly in the plasma and is made slowly. One exchange of a full plasma volume lowers it to roughly 38 units. Over the next two days some returns from the tissues, and the level settles near 55. A second exchange at that point lowers 55 to about 21, and rebound brings it back to around 32.
Now suppose the same protein is made quickly. After the first exchange the level reaches 38, but production pushes it back toward 70 within two days. A second exchange then lowers 70 to about 27, and it climbs back again. The identical procedure produces a very different curve, and the number of sessions needed to hold the level down is different too.
Now suppose the protein sits largely in the tissues. The first exchange barely changes the total in the body, and the blood level rebounds almost fully. Here more sessions would achieve little, and a physician would reasonably conclude that exchange is the wrong tool.
These scenarios show why a clinician needs the distribution and turnover of the target before proposing a schedule, and why a measured response beats an assumed one.
Why the Gap Between Sessions Matters as Much as the Count
Rebound has a practical effect on scheduling. Sessions spaced too far apart allow levels to return to where they began, and the benefit of the earlier session is lost. Sessions spaced closely, such as every other day in some medical courses, take advantage of the lowered level before it recovers.
Closely spaced sessions are used when the aim is to bring a harmful substance down quickly and keep it down before it rebounds. This pattern is common in hospital courses. Widely spaced sessions, for example weekly or monthly, give the body time to recover and are used for maintenance or for goals where speed is not needed. They also reduce cumulative stress on immunity and clotting.
The right interval depends on how quickly the target returns and how well the person tolerates the procedure. A plan that quotes a count without an interval is incomplete. The interval can also change as data come in. If levels return slowly, the gap can be lengthened. If they return quickly, it may be shortened, or the physician may conclude that plasma exchange is not the right tool for this target.
Reading the Labs Around Each Session
Because the schedule should follow the data, the timing and interpretation of labs matter.
Baseline tests are drawn before the first session. These establish where the person starts and may include blood counts, kidney and liver function, calcium, clotting measures, immunoglobulins and any marker relevant to the goal.
Tests drawn immediately after an exchange reflect dilution. Levels of many substances are artificially low at that moment, and they drift back in the hours that follow. A result right after a session therefore says what the exchange did mechanically, not where the person's steady level is.
Tests drawn just before the next session are more informative. They show how much has come back, which indicates the effect of rebound and production and helps decide whether the interval is right.
Tests drawn weeks later show whether a lasting change occurred. This is the measure that matters most if the aim is durable improvement, and it is the one most often missing from marketing. Lab results from before and after an exchange show part of the picture, though only part.
How Rebound Shapes the Structure of a Series
Although the details vary, a series follows recognizable patterns, and each one is a response to rebound.
An initial course is the most common design. A set of exchanges is scheduled over a short period, often several within one or two weeks, with the interval chosen to use the lowered level before rebound. Labs may be drawn before the first session and at intervals thereafter to see whether the target is moving. For most patients, Liondale recommends an initial series of three to six sessions, and what follows depends on how levels and symptoms respond.
A review point follows. After the initial course, the physician looks at what changed, both in measurements and in how the patient is doing. Decisions are made then: stop, continue with a lower frequency or add another course.
Maintenance schedules exist in some conditions where the substance returns and the condition tends to relapse. Exchanges are then spaced out, for example every few weeks, to keep the level in range. This is a long-term plan with its own monitoring, and it is different from a one-off course.
The least structured pattern is the repeated course at intervals, such as a series once or twice a year, which is sometimes proposed outside established indications. The rationale is that substances accumulate again, but the evidence that such a pattern improves health in people without a defined condition is limited, and it is reasonable to ask what is being measured and why that interval was chosen.
When One Session Is a Trial and When It Is Not Enough
A single session can be a complete plan only if the target is something that one exchange can meaningfully reduce, that does not rebound quickly and that does not need to be reduced further. Few chronic targets meet all three conditions.
A single session can also serve as a trial. In some contexts, a physician proposes one exchange to see how a person tolerates the procedure and whether a measurable marker changes before committing to more. This is a sensible approach as long as it is described as a trial and not as the whole treatment.
Where a single session is presented as a cleansing event with lasting effect, questions are warranted. The mechanics of dilution and rebound mean that the blood is not simply reset.
What Physicians Weigh Besides Rebound
Rebound is one input among several when a physician sets a plan.
The goal comes first. Is the aim to lower a specific substance, to relieve a condition, to test response or to explore a possible benefit? The strength of the evidence behind that goal limits how confidently a schedule can be chosen. The clinical trial evidence is more developed for some indications than for others.
The size of the patient matters. Plasma volume scales with body size, so larger people need more fluid exchanged to achieve the same fractional removal, and sessions take longer.
Safety limits matter, as the next section describes. Response matters too. Repeating a procedure that is not producing the expected change is not good medicine, and a plan with checkpoints, and a decision to continue, adjust or stop, is more reliable than a fixed number.
Finally, circumstances matter: venous access, other medications, other conditions and a person's own preferences.
What Repetition Costs the Body
Each exchange is a procedure with risks, and those risks add up across a series. Compared with giving blood, which takes whole blood once and lets the body rebuild, exchange is a longer procedure with more to monitor and more to recover from.
Immunoglobulins fall with every exchange. After a single session the level of protective antibodies drops substantially, and it recovers over weeks. Repeated sessions closely spaced can lower levels more deeply, and for some patients this raises the risk of infection. Monitoring of antibody levels and, in particular situations, replacement are part of careful practice.
Clotting factors are diluted by each exchange. When sessions are close together, clotting tests may remain abnormal, and this matters for anyone with a bleeding risk or a planned procedure.
Calcium is lowered by the citrate used to prevent clotting in the circuit. The effect is usually mild and manageable within a session, but a series demands consistent attention to calcium and sometimes supplementation.
Venous access is another factor. Repeated needle placement in the same veins, or a catheter that stays in place between sessions, carries risks of irritation, infection and clotting. These shape what is practical.
Medications that bind to plasma proteins may be removed in part, and their levels need review. This matters for any drug with a narrow range.
None of these risks is a reason to avoid the procedure when it is indicated. They are reasons to treat the schedule as a medical decision with a cost, not a package choice.
When the Rebound Evidence Is Thin
For many reasons people hear about, plasma exchange sits outside the established medical indications, and the evidence is smaller, earlier or mixed.
In these situations, the schedule cannot be justified by a trial that tested it. Trials typically examine a specific schedule in a specific condition, and results from one do not transfer to another. A physician who proposes a count in such a case is extrapolating, and a trustworthy one says so.
One example is the research on exchange in neurological conditions, where a trial tested a defined protocol of exchanges combined with albumin. That trial used a defined protocol, and what it did and did not show on brain fog is a good example. The lesson there is that a schedule comes from a protocol in a population and not from a general rule.
Where evidence is thin, the reasonable approach is transparency. The physician explains what is known, what is not, what will be measured and what would lead to stopping. The patient decides with that information.
When a Starting Range Turns Into a Fixed Promise
Because people search for a number, some providers offer one up front, and a starting range is not the problem. A range such as an initial series of three to six sessions is a reasonable way to begin when it is tied to measurement. The problem is a count that has stopped being a plan.
A few signs suggest that a number has not been earned. The count never changes, whatever a person's size, goal, labs or response. There is no mention of measurement, so no baseline, no interval check and no review point is planned. The count tracks the way sessions are sold and not the way medicine works, and a medical plan should be able to explain itself without reference to how it is packaged. For plasma exchange, the promise is a state such as a reset or renewal, which cannot be tested and cannot justify any number of sessions. Or the person recommending the count is not the one supervising the procedure and reviewing results, which leaves accountability unclear.
A starting range that is revisited after the first labs, adjusted for rebound and ended when it stops helping meets a different standard from a count that is fixed in advance.
Rebound When Exchange Is Paired With Other Treatments
In some conditions, plasma exchange is used alongside other treatments, and this changes how much rebound matters.
Immune-suppressing medicines reduce the production of harmful antibodies, so that the substance does not simply return after each exchange. In such cases, fewer sessions may be needed, because the exchange lowers the level and the medicine keeps it down.
Treatments that remove or neutralize a target by another route may reduce the need for exchange or make it unnecessary. Where exchange fits, and where another route fits better, is worth weighing.
Some people also ask about combining exchange with longevity-oriented medicines. Pairing exchange with rapamycin and metformin is one such idea, and the questions around it are still open. The practical point here is that any combination changes what is measured and when, and the schedule should reflect it.
Candidacy Comes Before Any Schedule
It is easy to start with a number when the better first question is whether the procedure is appropriate.
Before any schedule is set, a physician reviews the history, medications, lab results, veins and goals. Some people should not have plasma exchange, for example those with certain bleeding or cardiovascular conditions, severe allergies to replacement products or unstable circumstances. Candidacy and safety screening sets out who is a reasonable candidate and who is not.
If the answer is that a person is not a candidate, the schedule is irrelevant. If the answer is that they are, the schedule is set as a plan with checkpoints, and that plan is the physician's responsibility.
What a Good Answer Sounds Like
When a clinician is asked how many sessions are needed, or how fast levels come back, a good response has a recognizable shape. It starts with a question back: what are you hoping to accomplish, and what do your results show? The physician needs the goal and the data before offering anything. It describes the logic in terms of what each session does, how fast levels return and what the interval will be. It includes measurement, with baseline, mid-course and follow-up tests and an explanation of what each is meant to show. It sets decision points, so that after a certain number of sessions or a certain time the physician and patient review and decide whether to continue. It is honest about evidence, saying whether the schedule rests on trials, on practice or on extrapolation. And it leaves room to stop, naming what would end the series, including side effects, lack of response or a change in circumstances.
If the answer is only a number and a price, that does not meet the standard. A person is entitled to a clear plan, and the number should follow from it.
Practical Considerations Around Scheduling
Apart from the medical logic, a few practical matters affect how a series unfolds. Each session takes a couple of hours, so repeated visits need planning around work and travel, and a closely spaced course has to be feasible before it is chosen. Good venous access makes sessions smoother, and hydration the day before, a meal beforehand and warmth help. Some people feel tired afterward, so lighter days after a session are sensible, especially during a closely spaced course.
Medications taken regularly should be reviewed in advance, since timing around a session can matter. A log of sessions, results and symptoms supports decisions at review points and helps if you move between providers. For New York residents, it is worth choosing clinics that keep such records as a matter of routine.
Putting Rebound in Its Place
Rebound is why plasma exchange is a process and not an event. The level falls while the machine runs, climbs back as tissues release and the body produces more, and the plan that makes sense is the one built around that curve: when to measure, how far apart to schedule, when to review and when to stop.
A single session can be a trial. A short series can be a course aimed at a defined target. A longer schedule can be maintenance for a condition that tends to return. Each has its own logic, and none is right for everyone.
The next time someone offers a schedule, it helps to ask how the level is expected to behave between sessions and how that will be measured. If those answers are clear, the schedule is probably sound. If they are not, it is worth seeking a plan that rests on more than a guess. Readers who want to see how Liondale approaches these decisions can look at its plasma exchange service, which Lionel Bissoon leads.
Frequently Asked Questions
What is rebound in plasma exchange?
Rebound is the return of a substance to the blood from the tissues, and its continued production by the body, after plasma is removed. It is why levels climb back in the hours to days after a session.
How fast do levels come back after a session?
It depends on the substance. For one with a large tissue reservoir, a considerable portion of the removed amount can return within a day or two, while a substance confined mostly to the blood shows little rebound, and the pace of production by the body adds to the climb.
Does rebound mean the session did not work?
Not by itself. One exchange of a plasma volume lowers a circulating substance by about 60 to 65 percent, and some return is expected. What matters is whether the lowered level holds long enough to be useful for the goal, which is why labs are timed around sessions.
Why does spacing matter in a series?
Sessions spaced too far apart let levels return to where they began, while closely spaced sessions use the lowered level before it recovers. The right interval depends on how fast the target returns and how the person tolerates the procedure.
Does rebound change how many sessions are needed?
Yes. Rebound and production determine how long one exchange holds its effect, so they shape both the spacing and the length of a series. For most patients, Liondale recommends an initial series of three to six sessions, with what follows depending on response.
Which labs show rebound?
Baseline tests, tests just before the next session to show how much has come back and later tests to show whether a lasting change occurred. Tests drawn right after a session mostly reflect dilution.
Is one plasma exchange session enough?
Sometimes a single session serves as a trial, but one exchange of a plasma volume lowers a circulating substance by only about 60 to 65 percent and levels can rebound, so a single session is rarely a complete plan.
This page was written and medically reviewed by Lionel Bissoon, D.O., founder of Liondale Medical. Dr. Bissoon is a board-certified osteopathic physician specializing in anti-aging and concierge medicine on the Upper West Side of Manhattan.
This content is for educational purposes only and does not constitute medical advice. Individual results may vary. Consult a qualified physician before beginning any new treatment.
Published
You Might Also Enjoy...